Dabigatran/Cobicistat Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Very Serious. These medicines may interact and cause very harmful effects and are usually not taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Cobicistat may cause your body to absorb more dabigatran than expected.
What might happen:
Your blood levels of dabigatran may increase. This may cause serious bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking dabigatran and cobicistat together. Your doctor may want to change your medication. Let your healthcare professional know if the side effects of dabigatran increase or if you have any bleeding from the eyes, gums or nose; unusual bruising; dark stools; red or dark brown urine; and/or abdominal pain or swelling.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop or change the dosage of any medication before checking with them first.
- 1.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. June, 2021.
- 2.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited January 10, 2020.
- 3.Tybost (cobicistat) US prescribing information. Gilead Sciences, Inc. September, 2021.
- 4.Tybost (cobicistat) EMA summary of product characteristics. Gilead Sciences Limited May, 2014.
- 5.Evotaz (atazanavir and cobicistat) UK summary of product characteristics. Bristol-Myers-Squibb Company March, 2016.
- 6.Rezolsta (darunavir/cobicistat) UK summary of product characteristics. Janssen Pharmaceuticals Inc. March, 2016.
- 7.Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir) UK summary of product characteristics. Gilead Sciences, Inc March, 2016.
- 8.Evotaz (atazanavir and cobicistat) US prescribing information. Bristol-Myers-Squibb Company May, 2023.
- 9.Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir) US prescribing information. Gilead Sciences, Inc September, 2021.
- 10.Prezcobix (darunavir and cobicistat) US prescribing information. Janssen Pharmaceuticals, Inc. March, 2023.
- 11.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents Living with HIV. Department of Health and Human Services. Available at https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats -new-guidelines June 13, 2021.
- 12.Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Lozier J, Penzak SR, Hadigan C. Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers. Circulation 2016 Dec 06;134(23):1909-1911.
Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.